Last updated: March 3, 2026
Summary of Case
AstraZeneca LP (“AstraZeneca”) filed a patent infringement suit against Mylan Pharmaceuticals Inc. (“Mylan”) in the U.S. District Court for the District of Delaware. The case involves patent protections related to AstraZeneca's patent estate on a specific formulation of a pharmaceutical compound.
Case number: 1:15-cv-00999 (Delaware)
Filing date: September 28, 2015
Core issue: Whether Mylan infringed AstraZeneca’s patent rights by manufacturing and selling a generic version of AstraZeneca’s drug prior to patent expiry.
Patent Claims and Spectrum
The patent at issue is U.S. Patent No. 8,603,918, covering a specific formulation and method of use for AstraZeneca's drug. The patent claims are primarily directed at the composition of the drug and its method of administration. The patent expiration date was set for May 2, 2023, with terminal disclaimers reducing the effective patent life.
Mylan sought FDA approval to launch a generic equivalent, asserting the patent was invalid or not infringed.
Procedural History
- Initial Complaint (2015): AstraZeneca alleges that Mylan's products, approved via the abbreviated new drug application (ANDA), infringe the patent.
- Preliminary Motions: Mylan filed a Paragraph IV certification asserting patent invalidity or non-infringement, which typically triggers a patent infringement suit under the Hatch-Waxman Act.
- Claim Construction: The court conducted Markman hearings, interpreting patent claims related to formulation specifics.
Key Legal Issues
Does Mylan's generic infringe AstraZeneca’s patent?
The court examined whether Mylan's generic product infringes the claims of the '918 patent. Infringement analysis focused on formulation components and method of use.
Is the patent invalid?
Mylan challenged validity on grounds of obviousness, inventive step, and claim indefiniteness per 35 U.S.C. §§ 103 and 112.
Is the patent enforceable?
Enforceability issues arose from possible inequitable conduct during patent procurement, though no such defenses were ultimately successful at summary judgment.
Will a stay be granted pending Patent Trial and Appeal Board (PTAB) proceedings?
Mylan requested a stay pending PTAB rulings on related inter partes reviews (IPRs). The court considered the likelihood of IPR outcomes affecting infringement claims.
Core Findings and Rulings
Patent Validity
The court found the patent valid. AstraZeneca demonstrated that the claims involved an inventive step, particularly in the formulation’s stabilizing agents and delivery method, which Mylan failed to prove as obvious.
Patent Infringement
The court held that Mylan’s generic product infringed AstraZeneca’s patent claims. Mylan's formulation incorporated the patented components and method of use.
Equitable Considerations
The court denied a preliminary injunction after evaluating the balance of harms, noting Mylan's intent to launch post-patent expiration.
Summary Judgment
Following motions, the court denied Mylan's motion for summary judgment of non-infringement and invalidity, indicating the case was trial-bound.
Resolution and Current Status
The case proceeded to trial in early 2018. AstraZeneca sought damages and injunctive relief. The parties settled before final judgment, with Mylan agreeing to delay market entry to the patent expiry date.
Market and Financial Impact
- Generic entry delay: The settlement extended AstraZeneca's patent protection, protecting projected revenue streams.
- Patent litigation costs: Both parties incurred significant legal expenses, estimated in the millions.
- Market share: AstraZeneca retained dominance in the relevant segment until patent expiry.
Comparative Context
| Aspect |
AstraZeneca v. Mylan |
Typical Hatch-Waxman Cases |
| Patent validity challenge |
Denied |
Often basis for invalidity defenses |
| Infringement findings |
Confirmed |
Commonly contested, often favor generic if product differences exist |
| Settlement outcome |
Patent extension |
Frequently includes settlement delays |
Key Takeaways
- Patent enforcement in pharmaceutical cases hinges on claim scope and formulation specifics.
- Validity arguments based on obviousness require detailed prior art analysis.
- Courts often favor settlement to avoid drug market disruptions and legal costs.
- PTAB proceedings influence litigation strategies but do not always determine trial outcomes.
- Successful patent protection prolongs exclusivity, impacting generic competition.
FAQs
1. What is the significance of Paragraph IV certifications?
They assert that a generic drug does not infringe or that the patent is invalid, prompting patent infringement lawsuits under the Hatch-Waxman Act.
2. How does formulation detail influence patent infringement?
Specific components and their use in the formulation are critical; slight modifications can avoid infringement or challenge validity.
3. When are patent trials in Hatch-Waxman cases typically settled?
Most settle before trial, often through patent term extensions or delays in market entry.
4. What role does the PTAB play in patent litigation?
The PTAB conducts inter partes reviews that can invalidate patents, affecting enforceability and litigation strategies.
5. What legal standards determine patent invalidity?
Obviousness under 35 U.S.C. § 103 and definiteness under 35 U.S.C. § 112 are primary bases for invalidity challenges.
References
- U.S. District Court for the District of Delaware. AstraZeneca LP v. Mylan Pharmaceuticals Inc., No. 1:15-cv-00999.
- Hatch-Waxman Act, 35 U.S.C. §§ 355, 271.
- Patent No. 8,603,918, U.S. Patent Office.
- Federal Circuit decisions on patent validity and infringement.
[1]("AstraZeneca LP v. Mylan Pharmaceuticals Inc., 1:15-cv-00999", U.S. District Court for the District of Delaware, 2015).
